Skip to content
Disclosery

Casdin Capital, LLC

Follow

13F filer, CIK 1534261, New York, NY

Casdin Capital, LLC reported $1,199,325,239 across 32 holdings for the quarter ended 2025-09-30, in a 13F-HR filed 2025-11-14. Its ten largest share positions make up 84.52% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000919574-25-007006

Period
2025-09-30
Reported value
$1.2B
Holdings
32
Top 10 weight
84.52%
New
5
Sold out
6

Largest buys vs the previous quarter

SecurityShares changeApprox. value
TEMnew+294,127$23.7M
SPRYnew+1,600,000$16.1M
GPCRadded+330,000$9.24M
PRMEadded+1,600,000$8.86M
UNHnew+25,000$8.63M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
WGSreduced-500,000-$53.9M
VERVE THERAPEUTICS INCexited-4,095,571-$46M
BLFSreduced-1,000,000-$25.5M
CDXSexited-7,200,000-$17.6M
SRPTexited-990,097-$16.9M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2025

Share positions as resolved from 13F-HR 0000919574-25-007006, largest first. % of portfolio is the value over $1,199,325,239, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
WGSGENEDX HOLDINGS CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,507,164 shares; 2024Q4: 3,507,164 shares; 2025Q1: 3,507,164 shares; 2025Q2: 3,507,164 shares; 2025Q3: 3,007,164 shares 3,007,164$324M27.01%-500,000Timeline
BLFSBIOLIFE SOLUTIONS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 8,707,165 shares; 2024Q4: 8,707,165 shares; 2025Q1: 8,707,165 shares; 2025Q2: 7,707,165 shares; 2025Q3: 6,707,165 shares 6,707,165$171M14.27%-1,000,000Timeline
RVMDREVOLUTION MEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 4,114,283 shares; 2024Q4: 3,699,283 shares; 2025Q1: 3,697,933 shares; 2025Q2: 2,887,933 shares; 2025Q3: 2,647,333 shares 2,647,333$124M10.31%-240,600Timeline
LABSTANDARD BIOTOOLS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 71,254,677 shares; 2024Q4: 71,254,677 shares; 2025Q1: 76,075,636 shares; 2025Q2: 76,075,636 shares; 2025Q3: 77,558,856 shares 77,558,856$101M8.41%+1,483,220Timeline
RNAMAVIDITY BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,084,841 shares; 2024Q4: 2,045,000 shares; 2025Q1: 2,045,000 shares; 2025Q2: 1,775,000 shares; 2025Q3: 1,780,000 shares 1,780,000$77.6M6.47%+5,000Timeline
RLAYRELAY THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 9,251,108 shares; 2024Q4: 8,948,574 shares; 2025Q1: 9,098,574 shares; 2025Q2: 11,398,574 shares; 2025Q3: 11,341,381 shares 11,341,381$59.2M4.94%-57,193Timeline
ILMNILLUMINA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 750,000 shares; 2024Q4: 750,000 shares; 2025Q1: 595,000 shares; 2025Q2: 645,000 shares; 2025Q3: 525,000 shares 525,000$49.9M4.16%-120,000Timeline
GPCRSTRUCTURE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 700,000 shares; 2024Q4: 700,000 shares; 2025Q1: 700,000 shares; 2025Q2: 1,225,000 shares; 2025Q3: 1,555,000 shares 1,555,000$43.5M3.63%+330,000Timeline
BEAMBEAM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 775,000 shares; 2024Q4: 1,250,000 shares; 2025Q1: 1,425,562 shares; 2025Q2: 1,450,000 shares; 2025Q3: 1,600,000 shares 1,600,000$38.8M3.24%+150,000Timeline
ALNYALNYLAM PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 170,000 shares; 2024Q4: 140,000 shares; 2025Q1: 120,000 shares; 2025Q2: 81,500 shares; 2025Q3: 55,000 shares 55,000$25.1M2.09%-26,500Timeline
TEMTEMPUS AI INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 294,127 shares 294,127$23.7M1.98%newTimeline
NGNENEUROGENE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 524,616 shares; 2024Q4: 1,295,361 shares; 2025Q1: 1,295,361 shares; 2025Q2: 1,295,361 shares; 2025Q3: 1,295,361 shares 1,295,361$22.4M1.87%0Timeline
MAZEMAZE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 946,357 shares; 2025Q2: 758,857 shares; 2025Q3: 758,857 shares 758,857$19.7M1.64%0Timeline
PRMEPRIME MEDICINE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 367,175 shares; 2024Q4: 367,175 shares; 2025Q1: 367,175 shares; 2025Q2: 1,567,175 shares; 2025Q3: 3,167,175 shares 3,167,175$17.5M1.46%+1,600,000Timeline
SPRYARS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 1,600,000 shares 1,600,000$16.1M1.34%newTimeline
HIMSHIMS & HERS HEALTH INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 200,000 shares; 2025Q2: 230,000 shares; 2025Q3: 230,000 shares 230,000$13M1.09%0Timeline
DNLIDENALI THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 990,000 shares; 2024Q4: 990,000 shares; 2025Q1: 990,000 shares; 2025Q2: 890,000 shares; 2025Q3: 890,000 shares 890,000$12.9M1.08%0Timeline
SEPNSEPTERNA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 553,268 shares; 2025Q1: 553,268 shares; 2025Q2: 553,268 shares; 2025Q3: 553,268 shares 553,268$10.4M0.87%0Timeline
VCYTVERACYTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 666,308 shares; 2024Q4: 276,308 shares; 2025Q1: 276,308 shares; 2025Q2: 276,308 shares; 2025Q3: 276,308 shares 276,308$9.49M0.79%0Timeline
UNHUNITEDHEALTH GROUP INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 25,000 shares 25,000$8.63M0.72%newTimeline
INCYINCYTE CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 100,000 shares 100,000$8.48M0.71%newTimeline
GHGUARDANT HEALTH INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 350,000 shares; 2024Q4: 350,000 shares; 2025Q1: 250,000 shares; 2025Q2: 100,000 shares; 2025Q3: 100,000 shares 100,000$6.25M0.52%0Timeline
EXASEXACT SCIENCES CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 650,000 shares; 2024Q4: 650,000 shares; 2025Q1: 405,000 shares; 2025Q2: 90,000 shares; 2025Q3: 90,000 shares 90,000$4.92M0.41%0Timeline
BBOTBRIDGEBIO ONCOLOGY THERAPEUTQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 282,312 shares 282,312$3.27M0.27%newTimeline
ABSIABSCI CORPORATIONQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 973,260 shares; 2024Q4: 973,260 shares; 2025Q1: 973,260 shares; 2025Q2: 973,260 shares; 2025Q3: 973,260 shares 973,260$2.96M0.25%0Timeline
CTNMCONTINEUM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 296,666 shares; 2024Q4: 296,666 shares; 2025Q1: 148,333 shares; 2025Q2: 148,333 shares; 2025Q3: 148,333 shares 148,333$1.74M0.15%0Timeline
PACBPACIFIC BIOSCIENCES CALIF INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,035,859 shares; 2024Q4: 1,035,859 shares; 2025Q1: 723,767 shares; 2025Q2: 723,767 shares; 2025Q3: 723,767 shares 723,767$926K0.08%0Timeline
RXRXRECURSION PHARMACEUTICALS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 165,323 shares; 2025Q1: 165,323 shares; 2025Q2: 165,323 shares; 2025Q3: 165,323 shares 165,323$807K0.07%0Timeline
GLUEMONTE ROSA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 86,014 shares; 2024Q4: 86,014 shares; 2025Q1: 86,014 shares; 2025Q2: 86,014 shares; 2025Q3: 86,014 shares 86,014$637K0.05%0Timeline
IPSCCENTURY THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,212,316 shares; 2024Q4: 5,190,506 shares; 2025Q1: 3,212,316 shares; 2025Q2: 1,228,190 shares; 2025Q3: 1,228,190 shares 1,228,190$612K0.05%0Timeline
TNYATENAYA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 6,732,971 shares; 2024Q4: 6,732,971 shares; 2025Q1: 6,732,971 shares; 2025Q2: 361,969 shares; 2025Q3: 361,969 shares 361,969$586K0.05%0Timeline
DNAGINKGO BIOWORKS HOLDINGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 36,493 shares; 2024Q4: 36,493 shares; 2025Q1: 36,493 shares; 2025Q2: 36,493 shares; 2025Q3: 36,493 shares 36,493$532K0.04%0Timeline

Sold out in Q3 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
VERVE THERAPEUTICS INCVERVE THERAPEUTICS INC4,095,571$46Mshares
CDXSCODEXIS INC7,200,000$17.6Mshares
SRPTSAREPTA THERAPEUTICS INC990,097$16.9Mshares
LLYELI LILLY & CO8,500$6.63Mshares
SNDXSYNDAX PHARMACEUTICALS INC650,000$6.08Mshares
AGIOAGIOS PHARMACEUTICALS INC100,000$3.33Mshares

How Q3 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000919574-25-007006 base2025-11-14acceptance time not in the bulk data set